Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. The company's product candidate includes CBP-201. Connect Biopharma Holdings Limited is based in TAICANG, China.
| Revenue (Most Recent Fiscal Year) | $0.06M |
| Net Income (Most Recent Fiscal Year) | $-55.48M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.16 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2329.67% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -165.41% |
| Return on Assets (Trailing 12 Months) | -121.58% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.27 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.19 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 62.97M |
| Free Float | 48.74M |
| Market Capitalization | $138.54M |
| Average Volume (Last 20 Days) | 0.46M |
| Beta (Past 60 Months) | -0.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 58.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |